Moderna-Merck mRNA cancer vaccine helps prevent melanoma recurrence and death, new results show

Summary

A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return, The Philadelphia Inquirer reported on Thursday 22 October. Ars Technica reported that the personalized mRNA cancer vaccine 'cut melanoma death, recurrence by 42%', top-line results having been released after the trial was previously reported to have succeeded, and Scientific American said the new results show that the Moderna-Merck mRNA cancer vaccine helps prevent cancer recurrence and death.

Latest: Ars Technica reported that the personalized mRNA cancer vaccine 'cut melanoma death, recurrence by 42%' as top-line results were released, and Scientific American said the new results show that the Moderna-Merck mRNA cancer vaccine helps prevent cancer recurrence and death.

Written automatically by an AI from the articles' headlines and descriptions. It can contain errors: follow the links to read the articles.